Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.

Stoch, S A; Friedman, E; Maes, A; Yee, K; Xu, Y; Larson, P; Fitzgerald, M; Chodakewitz, J; Wagner, J A

Stoch, S A; Friedman, E; Maes, A; Yee, K; Xu, Y; Larson, P; Fitzgerald, M; Chodakewitz, J; Wagner, J A.

Affiliation

Stoch SA; Merck & Co, Inc, Whitehouse Station, NJ, USA. aubrey_stoch@merck.com

J Clin Pharmacol ; 49(4): 398-406, 2009 Apr.

Article in En | MEDLINE | ID: mdl-19246722

Subject(s)

Cytochrome P-450 CYP3A Inhibitors; Ketoconazole/administration & dosage; Midazolam/pharmacokinetics; Adult; Biological Availability; Computer Simulation; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Humans; Ketoconazole/adverse effects; Male; Midazolam/administration & dosage; Midazolam/adverse effects; Middle Aged; Models, Theoretical; Reproducibility of Results; Time Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Midazolam / Cytochrome P-450 CYP3A Inhibitors / Ketoconazole Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Humans / Male / Middle aged Language: En Year: 2009 Type: Article

Fulltext

XML

PubMed Links

Search on Google